Clinical trials: Viral Diseases
Chronic Hepatitis C
Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)
This is a three-part (Part A, Part B, and Part C), open-label, multicenter study of boceprevir in pediatric participants with chronic hepatitis C (CHC) genotype 1 (GT1).
- Trial name
- NCT01590225
- Testing
- Boceprevir, Peginterferon alpha-2b, Ribavirin
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Papillomavirus
Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects
This study is designed to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' human papillomavirus (HPV) vaccine in pre-teen and adolescent female subjects aged 9 - 17 years.
- Trial name
- NCT00996125
- Testing
- CervarixTM, Control
- Where
- China
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumors
Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors
The goal of this clinical trial is to evaluate the safety, tolerance, pharmacokinetics, and biological properties of recombinant human IL-21-expressing oncolytic vaccinia virus injection (hV01) in patients with advanced solid…
- Trial name
- NCT05914376
- Testing
- Recombinant human IL-21-expressing oncolytic vaccinia virus injection
- Where
- 2 sites in China
- Volunteers
- 24 people
- Sponsor
- Hangzhou Converd Co., Ltd.
Hepatitis C
Investigation Of The Effect Of Steady State Filibuvir On The Pharmacokinetics Of Oral Contraceptives (Levonorgestrel And Ethinyl Estradiol)
The purpose of this study is to estimate the effect of filibuvir on the pharmacokinetics of ethinyloestradiol [EE] and levonorgestrel [LN], to assess the safety and tolerability of 600 mg BID of filibuvir in healthy women and to…
- Trial name
- NCT00918476
- Testing
- filibuvir + Oral Contraceptives
- Where
- Belgium
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
RSV Infection
Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.
- Trial name
- NCT06843317
- Testing
- Candidate vaccine, SCB-1019T, AREXVY
- Where
- 5 sites in United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals USA, LLC
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) for 12 weeks in adults with chronic genotype 1, 2, 4, 5, or 6 hepatitis…
- Trial name
- ASTRAL-1 (NCT02201940)
- Testing
- SOF/VEL
- Where
- 80 sites in United States, Belgium and 7 more
- Volunteers
- 741 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus Infection
Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients
This study was to assess the safety and efficacy of Seraprevir in combination with sofosbuvir administered for 12 weeks in patients with Hepatitis C (HCV) genotype1.
- Trial name
- NCT04001608
- Testing
- Seraprevir, Sofosbuvir
- Where
- 22 sites in China
- Volunteers
- 206 people
- Sponsor
- Ginkgopharma CO., LTD
HIV Infections
The Safety and Effectiveness of MK-639 and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
To compare the effects on CD4 counts and safety of MK-639 (indinavir, IDV) and AZT administered concomitantly to MK-639 alone and AZT alone in HIV-1 seropositive patients.
- Trial name
- NCT00002443
- Testing
- Indinavir sulfate, Zidovudine
- Volunteers
- 780 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B
Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of GST-HG131 Tablets
To Evaluate the Safety, Tolerability and Pharmacokinetics of GST-HG131 Tablets in Single-center, Randomized, Double-blind, Placebo-controlled Multiple-dose, Single-dose, Multiple-dose Phase Ia Clinical Trials in Healthy Subjects
- Trial name
- NCT04499443
- Testing
- GST-HG131 tablets
- Where
- China
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Fujian Cosunter Pharmaceutical Co. Ltd
Influenza, Human
Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses
A single center trial to evaluate the effect of POLB 001 on inflammatory responses following an intradermal LPS challenge in healthy volunteers.
- Trial name
- NCT05765955
- Testing
- POLB 001
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Poolbeg Pharma plc
Healthy
A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001
DNA vaccines consist of small pieces of DNA also known as plasmids, and have several potential advantages over traditional vaccines. Thus far, DNA vaccines appear to be well tolerated in humans.
- Trial name
- NCT01403155
- Testing
- INO-3401 + EP
- Where
- 2 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Inovio Pharmaceuticals
Influenza
A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine
FLU-v is a vaccine that aims to protect against a wide range of flu viruses. The purpose of this study is to measure the immune responses induced by FLU-v vaccine.
- Trial name
- NCT02962908
- Testing
- FLU-v, adjuvanted FLU-v, Saline
- Where
- Netherlands
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- PepTcell Limited
Hepatitis B, Chronic
Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides
Both tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are potent antiviral agents for hepatitis B virus (HBV) and recommended by the American Association for the Study of Liver Disease (AASLD) as well as the…
- Trial name
- NCT04201808
- Testing
- Tenofovir Alafenamide 25 MG
- Where
- 10 sites in China
- Volunteers
- 100 people
- Sponsor
- New Discovery LLC
Hepatitis C, Chronic
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1
This observational study will evaluate the predictive value of rapid virological response (RVR) and early virological response (EVR) on sustained virological response (SVR) by stage of liver fibrosis in treatment-naïve patients…
- Trial name
- NCT01750216
- Where
- 14 sites in Poland
- Volunteers
- 196 people
- Sponsor
- Hoffmann-La Roche
Whole Cell Pertussis, Haemophilus Influenzae Type b
Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m
The purpose of the study is to evaluate the immunogenicity, safety and reactogenicity of a booster dose of DTPw-HBV/Hib-MenAC compared to DTPw-HBV/Hib given to healthy subjects at 15 to 24 months of age primed with 3 doses of…
- Conditions
- Whole Cell Pertussis, Haemophilus Influenzae Type b, Hepatitis B, Diphtheria
- Trial name
- NCT00136604
- Testing
- Tritanrix-HepB/Hib-MenAC, Mencevax ACWY, Tritanrix-HepB/Hiberix
- Where
- 3 sites in Thailand
- Volunteers
- 617 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19, Influenza A
Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel to Support Home Use
This study is designed to demonstrate the performance and usability of the the Panbio™ COVID-19/Flu A\&B Panel Self Test in the hands of patients/lay-users.
- Conditions
- COVID-19, Influenza A, Influenza Type B
- Trial name
- NCT06124638
- Testing
- Panbio™ COVID-19/Flu A&B Panel
- Where
- 2 sites in United States
- Volunteers
- 624 people
- Sponsor
- Abbott Rapid Dx
Covid19
Novaferon for COVID-19 Treatment Trial (NCTT-005)
A multicenter, randomized, double-blind, placebo-controlled trial for hospitalized moderate COVID-19 patients
- Trial name
- NCT04708158
- Testing
- Novaferon
- Where
- 22 sites in Japan
- Volunteers
- 385 people
- Sponsor
- Genova Inc.
Hepatitis C, Chronic
A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients
This 7 cohort study will evaluate the efficacy and safety of combination treatment with an HCV nucleoside polymerase inhibitor(RO5024048)and an HCV protease inhibitor(RO5190591/ITMN-191/danoprevir) in patients with chronic…
- Trial name
- NCT00801255
- Testing
- RO5024048, danoprevir
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 88 people
- Sponsor
- Hoffmann-La Roche
Sars-CoV2
Rhu-pGSN for Severe Covid-19 Pneumonia
Study Objectives: Primary To assess the efficacy (survival without organ failure on Day 14) of three doses of rhu-pGSN administered intravenously (IV) plus standard of care (SOC) to hospitalized subjects with a primary diagnosis…
- Trial name
- NCT04358406
- Testing
- Recombinant human plasma gelsolin (Rhu-pGSN)
- Where
- 3 sites in Romania, Spain
- Volunteers
- 64 people
- Sponsor
- BioAegis Therapeutics Inc.
Pneumonitis, SARS-CoV Infection
GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)
This clinical trial will evaluate the safety, tolerability and efficacy of GLS-1027 in the prevention of severe pneumonitis caused by SARS-CoV-2 infection
- Trial name
- NCT04590547
- Testing
- GLS-1027
- Where
- 17 sites in United States, Bulgaria and 3 more
- Volunteers
- 132 people
- Sponsor
- GeneOne Life Science, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.